| abstract |
Injectable insulin formulations with improved stability and rapid onset of action are described herein. The formulations may be for subcutaneous, intradermal or intramuscular administration. In the preferred embodiment, the formulations are administered by subcutaneous injection. The formulations contain insulin in combination with a chelator and dissolving agent, and optionally additional excipients. In the preferred embodiment, the formulation contains human insulin, a zinc chelator such as EDTA and a dissolving agent such as citric acid. These formulations are rapidly absorbed into the bloodstream when administered by subcutaneous injection. In the preferred embodiment, insulin is provided as a solution. In another embodiment, insulin is provided as a dry powder in a sterile vial. This is mixed with a diluent containing a pharmaceutically acceptable carrier, such as water, a zinc chelator such as EDTA and a dissolving agent such as citric acid shortly before or at the time of administration. In another embodiment, insulin is stored as a frozen mixture, ready for use in defrosting. |